Hair loss in women most often reflects a shift in the hair growth cycle or follicle sensitivity to androgens, not a simple vitamin deficiency. The two most common patterns are telogen effluvium, a diffuse shedding triggered by stress or illness, and female pattern hair loss, a progressive thinning driven by follicle miniaturization. Most cases are diagnosable and treatable, but the mechanism determines the treatment. This explainer covers how each process works, what the numbers mean, and where clinical guidance runs out.

How the hair growth cycle fails

Every scalp follicle cycles through three phases on its own clock. Anagen is the growth phase and lasts two to seven years on the scalp. Catagen is a brief transition of about two weeks. Telogen is a resting phase of roughly three months before the club hair sheds and the cycle restarts. At any moment, about 85 to 90 percent of scalp hairs sit in anagen, which is why normal shedding stays modest.

Telogen effluvium is a shift in cycle timing rather than follicle damage. A physiologic stressor pushes an unusually large cohort of follicles from anagen into telogen at once. Because the lag to shedding is about two to three months, the shedding peaks months after the trigger and then usually resolves. The follicles remain intact, so regrowth is expected once the trigger clears.

Female pattern hair loss works differently. Androgens, particularly dihydrotestosterone, bind receptors in genetically susceptible follicles and shorten anagen while lengthening the telogen-to-anagen transition. Each cycle produces a thinner, shorter hair until the follicle stops producing a visible shaft. The counterintuitive part is that this process can begin without any measurable hormone abnormality. Circulating androgen levels are frequently normal; the follicle's sensitivity is what changed.

Quantifying normal versus abnormal shedding

Shedding counts anchor the clinical picture. Losing 50 to 100 hairs per day is typical, and washing less often concentrates shedding on wash days, which inflates single-day counts. A useful reference is the wash test: collecting shed hairs on a consistent wash day and comparing counts over weeks is more informative than a single tally.

Pattern matters as much as volume. Telogen effluvium produces diffuse loss across the scalp. Female pattern hair loss concentrates thinning at the crown and mid-scalp with relative sparing of the frontal hairline, a distribution that differs from male pattern loss. Diffuse thinning with an intact frontal hairline in a woman should raise suspicion for pattern loss rather than pure shedding.

Feature Telogen effluvium Female pattern hair loss
Onset Weeks to months after a trigger Gradual, often over years
Distribution Diffuse across scalp Crown and mid-scalp, frontal sparing
Follicle status Intact Progressively miniaturized
Typical course Self-limited Progressive without treatment
Shedding volume Increased Often normal
Reversibility High if trigger resolves Partial; earlier treatment does better

Edge cases that change the workup

Several presentations mimic common hair loss but require different attention. Postpartum shedding is a predictable telogen effluvium driven by the fall in estrogen after delivery, typically peaking around three to four months postpartum. It resolves, but it can unmask underlying pattern loss that was previously quiet.

Traction alopecia comes from sustained tension on follicles, often from tight styling. Early change is reversible; prolonged tension can cause permanent scarring at the hairline. Trichotillomania, a compulsive pulling disorder, produces irregular patches with broken hairs of varying length.

Scarring alopecias are the edge case that changes urgency. Conditions such as lichen planopilaris and frontal fibrosing alopecia destroy follicles permanently, so time to diagnosis matters. A professional caveat: scalp symptoms like itching, burning, or tenderness alongside hair loss are not typical of pattern loss and warrant evaluation for an inflammatory cause.

Red-flag warnings that warrant prompt medical evaluation: Patchy hair loss with scaling, redness, or pustules Scalp pain, burning, or tenderness Rapid, diffuse shedding with fatigue, weight change, or heavy periods Hair loss accompanied by rash, joint pain, or fever Sudden shedding after starting a new medication Hairline recession with broken hairs or an urge to pull

Misconceptions that delay effective care

The most common misconception is that hair loss in women is usually a nutritional deficiency. Iron deficiency and thyroid disease can contribute and should be checked, but most cases trace to cycle disruption or androgen sensitivity, not low vitamins. Blind supplementation delays the diagnosis that would actually help.

A second misconception is that shedding and thinning are the same problem. They are not. Shedding is a cycle-timing issue with intact follicles. Thinning is a miniaturization issue with progressive follicle change. Treating one as the other produces disappointing results and lost time.

A third is that pattern hair loss is a male disease. It is common in women, and its female presentation differs in distribution, which is why it is often missed or misattributed to stress. Finally, the belief that hair loss is purely cosmetic understates its impact; it is a legitimate medical concern with measurable psychological effects and identifiable causes worth investigating.

Practical steps and thresholds

Start with documentation before intervention. Photograph the scalp under consistent lighting and track shedding on a fixed wash schedule for several weeks. Consistent records distinguish a self-limited shed from a progressive process and give a clinician something to work with.

Seek evaluation when shedding is heavy and persistent, when thinning follows a pattern rather than staying diffuse, or when any red flag is present. A clinician can examine the scalp, check for miniaturization, and order targeted labs such as ferritin, thyroid function, and, when indicated, androgen assessment. Avoid self-directed treatment with unproven products; the evidence base supports specific approaches under supervision, not general supplements.

Timing is a real variable. Pattern hair loss responds better when treated earlier, before miniaturization advances, so waiting to see if it resolves is a reasonable strategy for a clear telogen effluvium but a poor one for progressive thinning. When in doubt, get the pattern assessed rather than the shedding counted.

Where the evidence thins out

The mechanisms above are well established, but several practical questions lack clean answers. Optimal lab thresholds, particularly for ferritin in hair loss, remain debated, and different sources give different cutoffs. Reconcile thresholds with the evaluating clinician rather than applying a single number from the internet.

Long-term comparative data on treatment sequences in women are limited, and responses vary by cause and by individual. The honest position is that diagnosis is more reliable than prediction. A clear mechanism narrows the options; it does not guarantee a timeline or an outcome. That uncertainty is a reason to get evaluated early, not a reason to self-treat.